Generic Name and Formulations:
Ceftazidime 1g, 2g; pwd for IM or IV inj, or IV infusion after reconstitution; sodium content 2.3mEq/g.
Indications for TAZICEF:
Susceptible infections including lower respiratory tract (eg, pneumonia), skin and skin structure, UTIs, septicemia, bone and joint, gynecologic (eg, endometritis, pelvic cellulitis), meningitis, intraabdominal (eg, peritonitis).
Administer in upper outer quadrant of the gluteus maximus or lateral part of the thigh. Usual dose: 1g IV or IM every 8–12 hours. Uncomplicated UTIs: 250mg IV or IM every 12 hours. Complicated UTIs: 500mg IV or IM every 8–12 hours. Bone and joint: 2g IV every 12 hours. Uncomplicated pneumonia, mild skin and skin structure: 500mg–1g IV or IM every 8 hours. Serious gynecologic, intraabdominal, meningitis, or very severe life threatening (eg, immunocompromised): 2g IV every 8 hours. Lung infections: 30–50mg/kg IV every 8 hours; max of 6g/day. Renal dysfunction: CrCl 31–50mL/min: 1g every 12 hours; CrCl 16–30mL/min: 1g every 24 hours; CrCl 6–15mL/min: 500mg every 24 hours; CrCl <5mL/min: 500mg every 48 hours. Hemodialysis: 1g loading dose then 1g after each dialysis session. Peritoneal dialysis: 1g loading dose then 500mg every 24 hours.
Neonates: 30mg/kg IV every 12 hours. 1 month-12 years: 30–50mg/kg IV every 8 hours, max of 6g/day. Renal impairment: reduce dose.
Penicillin or other allergy. Renal or hepatic impairment, poor nutritional state, long term use: monitor prothrombin time. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Nephrotoxicity with concomitant aminoglycosides, diuretics (eg, furosemide). Antagonized by chloramphenicol. False (+) glucose test with Clinitest, Benedict's, or Fehling's soln.
Hypersensitivity reactions (eg, rash, pruritus, fever), local reactions, GI upset, elevated liver enzymes.
Vials 1g—1, 10, 25
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|